When Did Accutane Come Out?

Few acne treatments have changed dermatology as dramatically as Accutane. First approved in the U.S. in 1982, isotretinoin transformed the treatment of severe acne by producing results that earlier therapies often could not.

Quick Answer: When Did Accutane Come Out?

Accutane (isotretinoin) officially entered the U.S. market in May 1982, but its development spans decades of international dermatological research, regulatory evolutions, and safety enhancements.

Accutane’s history, however, began decades earlier and has included major scientific breakthroughs, evolving safety warnings, and increasingly strict pregnancy-prevention programs.

Early Treatments and the Vitamin A Breakthrough

Before the 20th century, acne remedies relied on harsh substances like arsenic, mercury, and yeast. And for the most part, acne treatments relied on those substances until a major clinical turning point in the early 1940s, when researchers found that high doses of vitamin A could significantly improve severe acne. However, therapeutic doses often caused severe liver toxicity.

This research helped establish the relationship between vitamin A and acne and laid the scientific foundation for the development of retinoids, a class of vitamin A-derived medications.

The Development of Isotretinoin

With the aim of creating a safer alternative, researchers at the Swiss pharmaceutical company Hoffmann-La Roche (known now simply as Roche) in Nutley, New Jersey worked to synthesize isotretinoin which is a synthetic retinoid derived from Vitamin A.

During the 1960s, researchers at the Swiss pharmaceutical company Hoffmann-La Roche (commonly known today as Roche) began developing synthetic retinoids derived from vitamin A. Isotretinoin was synthesized during this period and patented by Roche in 1969.

The drug was not initially developed specifically as an acne treatment. Researchers explored retinoids for several possible medical uses, including cancer prevention and disorders involving abnormal skin-cell growth. Its extraordinary effectiveness against severe acne would become clear later.

Clinical Trials and FDA Approval (1977–1982)

In 1977, Dr. Gary Peck led landmark clinical trials at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), in Bethesda, Maryland. Results reported in 1978 showed remarkable effectiveness, with a randomized study finding roughly 95% to 98% improvement among patients treated with isotretinoin.

The treatment was especially significant for patients with severe, treatment-resistant nodular and cystic acne, many of whom experienced long-lasting remission after completing treatment.

Following these studies, the U.S. Food and Drug Administration (FDA) officially approved isotretinoin under the brand name Accutane on May 7, 1982, for severe recalcitrant nodular acne. Isotretinoin is FDA-approved and remains available today.

Because isotretinoin can cause birth defects if taken during pregnancy, pregnancy-related safety precautions quickly became a central part of prescribing the medication.

Safety Warnings and Pregnancy Prevention Programs (1980s–2002)

As prescription volume grew, health agencies introduced stricter controls:

• 1980s: The FDA strengthened pregnancy warnings for Accutane, including prominent boxed warnings about the risk of severe birth defects.
• 1989: Roche launched the Accutane Pregnancy Prevention Program to reduce fetal exposure to isotretinoin.
• 1998: The FDA added warnings regarding potential psychiatric side effects, including depression and suicidal ideation, following emerging clinical reports.
• 2002: A more formal risk-management program called SMART, the System to Manage Accutane Related Teratogenicity, was introduced to strengthen pregnancy-prevention requirements.
• 2002–2003: Generic isotretinoin entered the U.S. market, including Amnesteem and Sotret in 2002, followed by Claravis in 2003.

Safety Controls and the 2006 iPLEDGE System

To unify and strengthen separate manufacturer risk-management programs, the FDA and isotretinoin manufacturers established a single nationwide system.

• 2006: The FDA introduced iPLEDGE, a mandatory risk-management program designed primarily to prevent fetal exposure to isotretinoin. iPledge is a mandatory program for patients taking Accutane, and it requires registration of patients, prescribers, pharmacies, and wholesalers, along with monthly authorization and pregnancy-testing requirements for patients who can become pregnant.
• Other laboratory monitoring, such as cholesterol, triglyceride, and liver-enzyme testing, may also be performed during isotretinoin treatment but is part of clinical care rather than a universal iPLEDGE requirement.
• 2009: Hoffmann-La Roche announced it would stop selling Accutane in the U.S., citing increased generic competition and the costs associated with litigation. The brand-name product was subsequently discontinued from the U.S. market, while generic isotretinoin remained widely available.

While effective at mitigating risk, iPLEDGE added significant friction to patient access, often making isotretinoin a costly, logistically burdensome last resort.

Modern Isotretinoin Care

More than four decades after its FDA approval, isotretinoin remains one of the most effective treatments available for severe, scarring, or treatment-resistant acne, backed by 40 years of research on this medication. Its ability to target multiple causes of acne, including oil production, clogged pores, inflammation, and acne-causing bacteria, makes it unique among acne treatments.

The way patients access isotretinoin care has also evolved. Teledermatology can now allow eligible patients to complete consultations, follow-up visits, and portions of the required monitoring remotely.

Today, platforms like Honeydew help streamline the medical process by connecting patients across the U.S. with licensed dermatology providers virtually, combining required safety monitoring with more accessible, specialized acne care.

Reviewed by David Futoran